Hekim C - Search Results

1

Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia.

Tracy SI, Venkatesh H, Hekim C, Heltemes-Harris LM, Knutson TP, Bachanova V, Farrar MA. Tracy SI, et al. Among authors: hekim c. Blood. 2022 Jul 28;140(4):335-348. doi: 10.1182/blood.2021015341. Blood. 2022. PMID: 35275990 Free PMC article.

2

Thymic regulatory T cells arise via two distinct developmental programs.

Owen DL, Mahmud SA, Sjaastad LE, Williams JB, Spanier JA, Simeonov DR, Ruscher R, Huang W, Proekt I, Miller CN, Hekim C, Jeschke JC, Aggarwal P, Broeckel U, LaRue RS, Henzler CM, Alegre ML, Anderson MS, August A, Marson A, Zheng Y, Williams CB, Farrar MA. Owen DL, et al. Among authors: hekim c. Nat Immunol. 2019 Feb;20(2):195-205. doi: 10.1038/s41590-018-0289-6. Epub 2019 Jan 14. Nat Immunol. 2019. PMID: 30643267 Free PMC article.

3

Immunology and immunotherapy of chronic myeloid leukemia.

Ilander M, Hekim C, Mustjoki S. Ilander M, et al. Among authors: hekim c. Curr Hematol Malig Rep. 2014 Mar;9(1):17-23. doi: 10.1007/s11899-013-0190-1. Curr Hematol Malig Rep. 2014. PMID: 24390549 Review.

4

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models.

Hekim C, Ilander M, Yan J, Michaud E, Smykla R, Vähä-Koskela M, Savola P, Tähtinen S, Saikko L, Hemminki A, Kovanen PE, Porkka K, Lee FY, Mustjoki S. Hekim C, et al. Cancer Immunol Res. 2017 Feb;5(2):157-169. doi: 10.1158/2326-6066.CIR-16-0061-T. Epub 2017 Jan 10. Cancer Immunol Res. 2017. PMID: 28073775

5

Complex formation between human prostate-specific antigen and protease inhibitors in mouse plasma.

Hekim C, Riipi T, Zhu L, Laakkonen P, Stenman UH, Koistinen H. Hekim C, et al. Prostate. 2010 Apr 1;70(5):482-90. doi: 10.1002/pros.21082. Prostate. 2010. PMID: 19937596

6

Evaluation of peptides as protease inhibitors and stimulators.

Koistinen H, Hekim C, Wu P, Närvänen A, Stenman UH. Koistinen H, et al. Among authors: hekim c. Methods Mol Biol. 2014;1088:147-58. doi: 10.1007/978-1-62703-673-3_10. Methods Mol Biol. 2014. PMID: 24146402

7

Novel peptide inhibitors of human kallikrein 2.

Hekim C, Leinonen J, Närvänen A, Koistinen H, Zhu L, Koivunen E, Väisänen V, Stenman UH. Hekim C, et al. J Biol Chem. 2006 May 5;281(18):12555-60. doi: 10.1074/jbc.M600014200. Epub 2006 Mar 9. J Biol Chem. 2006. PMID: 16527822 Free article.

8

Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors.

Pakkala M, Hekim C, Soininen P, Leinonen J, Koistinen H, Weisell J, Stenman UH, Vepsäläinen J, Närvänen A. Pakkala M, et al. Among authors: hekim c. J Pept Sci. 2007 May;13(5):348-53. doi: 10.1002/psc.849. J Pept Sci. 2007. PMID: 17436344

9

Development of peptides specifically modulating the activity of KLK2 and KLK3.

Koistinen H, Närvänen A, Pakkala M, Hekim C, Mattsson JM, Zhu L, Laakkonen P, Stenman UH. Koistinen H, et al. Among authors: hekim c. Biol Chem. 2008 Jun;389(6):633-42. doi: 10.1515/BC.2008.076. Biol Chem. 2008. PMID: 18627344 Review.

10

Identification of IGFBP-3 fragments generated by KLK2 and prevention of fragmentation by KLK2-inhibiting peptides.

Hekim C, Riipi T, Weisell J, Närvänen A, Koistinen R, Stenman UH, Koistinen H. Hekim C, et al. Biol Chem. 2010 Apr;391(4):475-9. doi: 10.1515/BC.2010.039. Biol Chem. 2010. PMID: 20180640

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters